

Appendix 3Y

Change of Director's Interest Notice

Name of entity	Impression Healthcare Limited
ABN	93 096 635 246

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Sudhanshu AGARWAL
Date of last notice	4 May 2020

Part 1 - Change of director's relevant interests in securities

Direct or indirect interest	Direct and Indirect
Nature of indirect interest	Dr Agarwal is a shareholder, CEO and director of Cannvalate Pty Ltd ("Cannvalate"). Positions disclosed in this Appendix 3Y are held by Cannvalate. Dr Agarwal does not have sole discretion over the acquisition or disposal of these positions.
Date of change	29 June 2020
No. and class of securities held prior to change	<ul style="list-style-type: none"> 32,000,000 fully paid ordinary shares ("IHL") 14,000,000 \$0.06 unlisted options expiry 01-Dec-20 16,000,000 \$0.08 unlisted options expiry 01-Dec-20 18,000,000 \$0.10 unlisted options expiry 01-Dec-20 20,000,000 \$0.12 unlisted options expiry 01-Dec-20 20,000,000 \$0.14 unlisted options expiry 01-Dec-20
Number and class of securities acquired	<ul style="list-style-type: none"> 4,000,000 fully paid ordinary shares ("IHL"); and 32,303,593 performance rights; and 200,000,000 \$0.20 unlisted options expiry 30-Sep-21
Number and class of securities disposed	Nil
Value/Consideration	Nil
No. of securities held after change	<p>Direct</p> <ul style="list-style-type: none"> 4,000,000 fully paid ordinary shares ("IHL") 32,303,593 performance rights 200,000,000 \$0.20 unlisted options expiry 30-Sep-21 <p>Indirect</p> <ul style="list-style-type: none"> 32,000,000 fully paid ordinary shares ("IHL") 14,000,000 \$0.06 unlisted options expiry 01-Dec-20 16,000,000 \$0.08 unlisted options expiry 01-Dec-20 18,000,000 \$0.10 unlisted options expiry 01-Dec-20 20,000,000 \$0.12 unlisted options expiry 01-Dec-20 20,000,000 \$0.14 unlisted options expiry 01-Dec-20
Nature of change	CMO remuneration package approved at EGM on 26 June 2020

Part 2 – Change of director's interests in contracts – no change

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

Appendix 3Y

Change of Director's Interest Notice

Name of entity	Impression Healthcare Limited
ACN	93 096 635 246

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Joel LATHAM
Date of last notice	10 September 2019

Part 1 - Change of director's relevant interests in securities

Direct or indirect interest	Direct
Nature of indirect interest	n/a
Date of change	1 July 2020
No. and class of securities held prior to change	<ul style="list-style-type: none"> • 10,245,795 IHL ordinary shares • 4,237,500 IHLOB options • 6,000,000 unlisted performance rights • 200,000 unlisted \$0.08 Options expiry 30-Sep-21
Number and class of securities acquired	<ul style="list-style-type: none"> • 1,583,334 IHL fully paid shares; and • 4,043,946 IHL fully paid shares (voluntary escrow); and • 750,000 unlisted \$0.05 Options expiry 03-Sep-25; and • 750,000 unlisted \$0.05 Options expiry 03-Sep-25 (voluntary escrow); and • 1,500,000 unlisted \$0.05 Options expiry 03-Sep-26 (voluntary escrow); and • 1,500,000 unlisted \$0.05 Options expiry 03-Sep-27 (voluntary escrow)
Number and class of securities disposed	Nil
Value/Consideration	Nil – issued as part of CEO remuneration for FY20 & FY21
No. of securities held after change	<ul style="list-style-type: none"> • 11,829,129 IHL ordinary shares • 4,237,500 IHLOB options • 5,000,000 unlisted performance rights • 200,000 unlisted \$0.08 Options expiry 30-Sep-21 • 4,043,946 IHL fully paid shares (voluntary escrow) • 750,000 unlisted \$0.05 Options expiry 03-Sep-25 • 750,000 unlisted \$0.05 Options expiry 03-Sep-25 ESC • 1,500,000 unlisted \$0.05 Options expiry 03-Sep-26 ESC • 1,500,000 unlisted \$0.05 Options expiry 03-Sep-27 ESC
Nature of change	CEO remuneration package approved at EGM on 26 June 2020 and conversion of 1m performance rights

Part 2 – Change of director's interests in contracts - No change

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a